A systematic review and meta-analysis of anti-adhesion molecule therapy in patients with active Crohn's disease

Scandinavian Journal of Gastroenterology

Volumn 44, Issue 12, 2009, Pages 1435-1442

  Li, Yi ^a   Tian, Yun ^b   Yu, Chao ^a   Zhu, Weiming ^a   Li, Jieshou ^a  

^a NANJING UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Anti adhesion molecule therapy; Crohn?s disease; Inflammatory bowel disease; Meta analysis

Indexed keywords

ALICAFORSEN; CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; NATALIZUMAB; PLACEBO; VEDOLIZUMAB;

ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; MEDLINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; RISK FACTOR; SCISEARCH; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; CELL ADHESION MOLECULES; CROHN DISEASE; HUMANS; IMMUNOLOGIC FACTORS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 72449168974     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365520903367254     Document Type: Article

References (43)

1. BaumgartDC,SandbornWJ.Gastroenterology2-Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57.
2. Colombel JF, Watson AJM, Neurath MF. The 10 remaining mysteries of inflammatory bowel disease. Gut 2008;57: 429-33.
3. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998;115:182-205.
4. Danese S, de la Motte C, Sturm A, Vogel JD, West GA, Strong SA, et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 2003;124:1249-64. (Pubitemid 36531801)
5. Scaldaferri F, Sans M, Vetrano S, Graziani C, De Cristofaro R, Gerlitz B, et al. Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J Clin Invest 2007;117:1951-60.
6. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration-the multistep paradigm. Cell 1994;76:301-14.
7. Berlin C, Bargatze RF, Campbell JJ, Vonandrian UH, Szabo MC, Hasslen SR, et al. Alpha-4 integrins mediate lymphocyte attachment and rolling under physiological flow. Cell 1995;80:413-22.
8. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60-66.
9. Kuhlman P, Moy VT, Lollo BA, Brian AA. The accessory function of murine intercellular-adhesion molecule-1 in lymphocyte-t activation-contributions of adhesion and coactivation. J Immunol 1991;146:1773-82.
10. Simmons D, Makgoba MW, Seed B. Icam, an adhesion ligand of Lfa-1, is homologous to the neural cell-adhesion molecule Ncam. Nature 1988;331:624-7.
11. Meenan J, Spaans J, Grool TA, Pals ST, Tytgat GNJ, vanDeventer SJH. Altered expression of alpha(4)beta(7), a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation Gut 1997;40:241-6.
12. Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn's disease: Beyond antagonists of tumour necrosis factor. Lancet 2008;372:67-81.
13. Rutgeerts P, Van Deventer S, Schreiber S. Review article: The expanding role of biological agents in the treatment of inflammatory bowel disease--focus on selective adhesion molecule inhibition. Aliment Pharmacol Ther 2003;17: 1435-50.
14. Stefanelli T, Malesci A, De la Rue SA, Danese S. Antiadhesion molecule therapies in inflammatory bowel disease: Touch and go. Autoimmun Rev 2008;7:364-9.
15. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clin Trials 1996;17:1-12.
16. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609-13. (Pubitemid 28380142)
17. Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, et al. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment Pharmacol Ther 2002;16:1761-70.
18. Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001;120:1339-46.
19. Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease Gut 2002;51:30-36.
20. Yacyshyn BR, Schievella A, Sewell KL, Tami JA. Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1. Clin Exp Immunol 2005;141:141-7.
21. Feagan BG, Sandborn WJ, Hass S, Niecko T, White J. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol 2007;102:2737-46. (Pubitemid 350179328)
22. Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflammatory Bowel Dis 2007;13:2-11.
23. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998;114:1133-42.
24. Gordon FH, Lai CWY, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha 4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-74.
25. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask- Madsen J, Rutgeerts P, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32.
26. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25.
27. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial. Gastroenterology 2007;132:1672-83. (Pubitemid 46695722)
28. Yacyshyn B, Chey WY, Wedel MK, Yu RZ, Paul D, Chuang E. A randomized, double-masked, placebocontrolled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 2007;5: 215-20.
29. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JWD, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha 4 beta 7 integrin. Clin Gastroenterol Hepatol 2008;6:1370-7.
30. Mudter J, Neurath MF. Apoptosis of T cells and the control of inflammatory bowel disease: Therapeutic implications. Gut 2007;56:293-303.
31. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34.
32. Mrowietz U, Boehncke WH. Leukocyte adhesion: A suitable target for anti-inflammatory drugs. Curr Pharm Des 2006;12:2825-31.
33. Van Assche G, Rutgeerts P. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases-I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005;288:G169-74.
34. Peyrin-Biroulet L, Deltenre P, Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53.
35. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab- A randomized trial. Ann Intern Med 2007;146:829-38.
36. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-28.
37. Leung Y, Panaccione R. Anti-adhesion molecule strategies for Crohn disease. Biodrugs 2008;22:259-64.
38. MacDonald JK, McDonald JWD. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007;1:CD006097.
39. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8.
40. Langer-Gould A, AtlasSW,GreenAJ, BollenAW,PelletierD. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81.
41. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-33.
42. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohns-disease Gut 1994;35:360-2.
43. Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology 2001;121:255-60.